Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Mometasone furoate 400 μg once daily is more efficacious than budesonide 400 μg once daily in improving asthma symptoms in patients with moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Once-daily, evening administration of mometasone furoate dry powder inhaler improves pulmonary function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 282s Year: 2003
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Reduction in oral corticosteroid use with mometasone furoate DPI improves health-related quality of life in patients with severe persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 395s Year: 2002
Safety and efficacy of momethason furoate for usage in school children with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 290s Year: 2003
Once daily ciclesonide delivered via pMDI is effective and safe for the treatment of mild-to-moderate persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 208s Year: 2006
Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with mild to moderate asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Twice-daily fluticasone propionate (fp)/formoterol fumarate (fm) HFA PMDI combination therapy is safe, efficacious and reduces asthma exacerbations in patients with moderate to severe asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014
The pharmacokinetics of mometasone furoate administered by dry powder inhaler following single and multiple dosing in patients with mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Once-daily mometasone furoate dry powder inhaler preserves lung function, reduces symptoms, and delays exacerbations in patients with COPD previously maintained on ICS Source: Eur Respir J 2003; 22: Suppl. 45, 4s Year: 2003
Efficacy and safety of combined mometasone furoate/formoterol 200/10μg in persistent asthmatics Source: Annual Congress 2010 - Aspects of severe asthma Year: 2010
Once-daily budesonide/formoterol via a single inhaler is effective in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Does health-related quality of life improve with QD and BID dosing of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids? Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003
Mometasone furoate reduces oral corticosteroid requirements and permits recovery of hypothalamic-pituitary-adrenal axis function in patients with severe persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 407s Year: 2002
Health-related quality of life effects of mometasone furoate dry-powder inhaler (MF DPI) in patients with mild to moderate persistent asthma previously using inhaled corticosteroids Source: Eur Respir J 2003; 22: Suppl. 45, 283s Year: 2003
Fluticasone furoate (FF), an inhaled corticosteroid (ICS), is efficacious in asthma patients symptomatic on low doses of ICS therapy Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Efficiency of once-daily mometasone furoate in school children with seasonal allergic rhinitis and severe nasal congestion Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006